

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INSIDE INFORMATION UPDATE ON PROFIT GUARANTEE IN RELATION TO ACQUISITION OF 70% EQUITY INTEREST IN GUANGZHOU SHENGSHIYUAN TRADING COMPANY LIMITED

This announcement is made by Yestar Healthcare Holdings Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 11 November 2016 (the “Announcement”) in respect of, amongst other things, the acquisition of 70% equity interests in Guangzhou Shengshiyuan Trading Company Limited (“Shengshiyuan”) and announcements of the Company dated 14 June 2023, 6 March 2024 and 8 April 2024 (the “Arbitration Announcements”) in relation to arbitration from two vendors of Shengshiyuan against the Company (the “First Arbitration”) and (the “Second Arbitration”). Unless otherwise stated herein, capitalized terms used herein shall have the same meanings as those defined in the Announcement and Arbitration Announcements.

The Group has recently received a withdrawal decision from Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Centre) (the “Arbitration Centre”) for the termination of the Second Arbitration as the Company and one of the vendors of Shengshiyuan has reached a mutual consent on the purchase of his remaining 3% of equity interest of Shengshiyuan.

The Company will keep the shareholders and potential investors of the Company informed of any further significant development in relation to the final decision of revocation of verdict results concluded on 28 February 2024 in relation to the First Arbitration as and when appropriate as the legal proceeding is in progress.

Shareholders of the Company and the public are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
CEO and executive Director

Hong Kong, 22 July 2024

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Ms. Wang Hong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.